

ERN eUROGEN Supporting Partner Agreement: Organisations (Annex 4 of Governance Statutes)

v.2024-01-12

Agreement between the European Reference Network (ERN) for Rare Urogenital Diseases and Complex Conditions (ERN eUROGEN) and the European Society for Paediatric Urology (ESPU)

An email was sent to the ERN eUROGEN Strategic Board asking them to vote, and the input of ESPU as a Supporting Partner was welcomed unanimously by all respondents.

ESPU is therefore officially recognised by ERN eUROGEN as a Supporting Partner and ERN eUROGEN affirms its commitment to work in collaboration with ESPU [and their representative(s)] for the benefit of patients living with rare urogenital diseases and complex conditions, under the leadership of Prof. Wout Feitz and Radboudumc, Nijmegen in The Netherlands.

Terms of collaboration between ERN eUROGEN and ESPU:

- ERN eUROGEN and ESPU agree to work in collaboration, where possible, on areas of common strategic interest.
- The agreement is for a 3-year period and will be then re-evaluated for a further 3-year period.
- In conveying their opinions and input, ERN eUROGEN and ESPU will be respectful of the viewpoints and opinions of others and ensure criticism is constructive, to ensure maintenance of the very high standards of professionalism that ERN eUROGEN adheres to. An open and collaborative debate where all individuals can feel respected and valued is a core principle.
- ESPU accepts the ERN eUROGEN Governance Statutes and ERN eUROGEN Conflict of Interests (COI) Policy.
- One or more representatives of ESPU and ERN eUROGEN should meet (virtually or face-to-face) at least twice a year concerning collaboration, expectations, and future directions.
- One representative of ESPU may attend the annual ERN eUROGEN Strategic Board meeting with no financial compensation by ERN eUROGEN and with no voting rights but an advisory status and informative role.
- A presentation can be given by a ESPU representative at the annual ERN eUROGEN Strategic Board meeting to describe recent developments, expectations, and future directions.
- A presentation can be given at the annual ESPU meeting by the ERN eUROGEN HCP Network Coordinator Representative or his Sub-Representative to give an update on ERN eUROGEN activities.
- ERN eUROGEN and ESPU will collaborate on webinars In the ERN eUROGEN webinar programme, where appropriate.
- ESPU members will be invited to collaborate on clinical guidelines and clinical decision support tools development, where relevant and appropriate.
- ERN eUROGEN and ESPU will disseminate relevant information from each other through their communication channels.
- If ESPU wishes to terminate the partnership with ERN eUROGEN, due to COI, a difference in direction, or other reasons, they should write to the ERN eUROGEN HCP Network Coordinator Representative explaining the reasons for the termination. The ERN Coordination Team will review this and then send a letter to ESPU to end the partnership.

- If ERN eUROGEN wishes to terminate the partnership with ESPU due to COI, difference in direction, or other reasons, after an additional consultation has been offered to exchange views, discuss changes in collaboration, and future options, the ERN eUROGEN Coordination Team will send a letter to ESPU to end the partnership.

Signed:




Prof. Marc-David LECLAIR, Secretary

The European Society of Pediatric Urology

Date: 27/01/2024

Signed:



Prof Wout Feitz

ERN eUROGEN HCP Network Coordinator Representative

Date: 06/02/2024